Medical Device Innovation

Faster healing for
diabetic foot ulcers

An automated light and sound therapy device that integrates into existing clinic workflows — delivering repeatable, standardized treatment in under 20 minutes.

the problem

Diabetic foot ulcers are common, costly, and deadly

Current care is effective but labor-heavy. Advanced adjunct therapies often don't fit routine clinic workflows — creating a critical gap in treatment scale.

18.6M

People affected annually

Worldwide

1.6M

New U.S. DFU cases

Per year

$9-13B

Annual economic burden

U.S. incremental cost

24wk

Typical treatment duration

Standard of care

clinical gaps

Why DFUs remain hard to treat at scale

  • Labor-intensive standard care

    Debridement, offloading, dressings, infection control — high visit cadence with variable clinician technique.

  • Bulky adjunct systems

    Existing devices require a complex setup that doesn't align with outpatient clinic workflows.

  • Poor repeatability

    Hard to target consistently across different clinicians and visits, limiting treatment efficacy.

  • High cost barriers

    Complex supply chains and expensive consumables limit adoption in routine care settings.

The opportunity

Scalable, repeatable clinic workflows that speed healing and reduce downstream complications — through automated adjunct therapy that fits seamlessly into existing care pathways.

WHAT'S NEEDED

A more effective and automated adjunct DFU therapy that integrates into existing clinical workflows without disruption.

Bridging the gap between clinical efficacy and clinical reality

Designed to bring proven therapeutic modalities into routine outpatient workflows — automatically.

Dual complementary modality

Photobiomodulation (PBM) and focused shockwave therapy (ESWT) delivered in one streamlined procedure.

our solution

Automated sound + light therapy for routine DFU care

A point-of-care platform designed to integrate into existing clinical pathways in under 20 minutes per visit.

Standardized targeting

Foot-shaped cradle positions the wound consistently visit-to-visit, independent of operator technique.

AI-automated therapy

Image-based AI targeting of treatment zones enables seamless automation with minimal clinician input.

the product

Lumipulse — first-of-its-kind combination therapy

The first device to combine photobiomodulation therapy and extracorporeal shockwave therapy in a single automated platform — designed specifically for outpatient DFU care.

Dual PBM + ESWT modality in one procedure
Automated therapy reduces workflow burden
Fits existing outpatient DFU pathways
≤20 minute add-on to routine visits
STATUS: Concept design - patent filed - ESWT technology licensed

STEP 01

Position

Place foot into standardized cradle targeting plantar ulcers

clinical workflow

Built for routine DFU clinic visits

Fast setup, standardized positioning, automated therapy — designed for throughput.

STEP 01

Couple

Apply disposable coupling pad for acoustic consistency

STEP 01

ESWT

Focused shockwave therapy pulses delivered (~10 min)

STEP 01

PBM

Red + near-infrared light dose administered (~10 min)

STEP 01

Document

Auto-log presets, dose, operator, and timestamp

≤20 min

Add-on to routine visit

Automated

Only setup time from clinic

Standardized

Consistent across operators

Photobiomodulation (PBM)

Red and near-infrared light modulates inflammation and supports cellular energy processes as an adjunct to standard care.

6.72×

Odds ratio for faster ulcer area reduction vs. control

Controlled randomized DFU trials

Focused ESWT (shockwave)

Mechanical stimulus promotes tissue repair signaling, angiogenesis, and remodeling as an adjunct to standard care.

1.57×

Higher complete healing rates vs. the standard of care

Systematic review/meta-analysis across 10 RCTs

CORE THESIS

Combining ESWT + PBM in a single clinic workflow will improve treatment outcomes through complementary mechanisms of action, while automated therapy administration will improve adoption rates across care settings.

clinical evidence

Built on proven therapeutic modalities

Both ESWT and PBM have demonstrated clinical benefit in DFU care. Lumisonix combines and automates both in a single device.

Team Member

CTO & Co-Founder

Background and credentials placeholder — to be provided by the team.

Team Member

Clinical Advisor

Background and credentials placeholder — to be provided by the team.

Team Member

Engineering Lead

Background and credentials placeholder — to be provided by the team.

our team

Built by clinicians and engineers

Filip Peters

CEO & Co-Founder

Background and credentials placeholder — to be provided by the team.

Our team combines deep clinical expertise in wound care with medical device engineering and regulatory experience.

Get in touch

Interested in Lumisonix?

Whether you're a clinician, investor, or potential partner, we'd love to hear from you.